MYDA Advisors’s Gilead Sciences GILD Stock Holding History

MYDA Advisors’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-10,000	Closed	-$716K	–	140
2017 Q4	$716K	Buy	+10,000	New	+$759K	0.32%	74

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Parnassus Investments San Francisco, California $34.1B AUM 20.22% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

MYDA Advisors's GILD Position: Q1 2018 in Review

MYDA Advisors sold out of Gilead Sciences (GILD) in Q1 2018, closing a stake of 10,000 shares — an estimated $716K sold.

MYDA Advisors first reported a position in GILD in Q4 2017 and held it in 1 quarter. The position peaked at $716K in Q4 2017. 1,563 funds tracked by Wall St. Rank hold GILD as of Q1 2018.

MYDA Advisors reported no remaining Gilead Sciences position as of Q1 2018 after selling out during the quarter.
MYDA Advisors sold 10,000 Gilead Sciences shares in Q1 2018, an estimated $716K.
MYDA Advisors first reported a position in Gilead Sciences in Q4 2017 and held it in 1 quarter.
MYDA Advisors's Gilead Sciences position peaked at $716K in Q4 2017.
1,563 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2018.

Based on MYDA Advisors's 13F filing for Q1 2018, filed 10 May 2018.